In Section C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will acquire treatment until eventually sickness progression or the participants are unable to tolerate the study drugs. - Participant consumed grapefruit or grapefruit products and solutions within 3 days previous https://abbv-744-clinical-trial-p25790.blogsuperapp.com/32464010/not-known-factual-statements-about-abbv-744-preclinical-studies-and-results